Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections

被引:4
作者
Miyashita, Naoyuki [1 ]
Nakamori, Yasushi [2 ]
Ogata, Makoto [1 ]
Fukuda, Naoki [1 ]
Yamura, Akihisa [1 ]
Ishiura, Yoshihisa [3 ]
Ito, Tomoki [1 ]
机构
[1] Kansai Med Univ, Dept Internal Med 1, Div Resp Med Infect Dis & Allergol, 2-3-1 Shin Machi, Hirakata 5731191, Japan
[2] Kansai Med Univ, Dept Emergency Med, Med Ctr, Moriguchi 5708507, Japan
[3] Kansai Med Univ, Dept Internal Med 1, Div Resp Med Oncol & Allergol, Med Ctr, Moriguchi 5708507, Japan
来源
VIRUSES-BASEL | 2023年 / 15卷 / 06期
关键词
sotrovimab; monoclonal antibody; COVID-19; Omicron variant; SARS-CoV-2;
D O I
10.3390/v15061300
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Sotrovimab, an antibody active against severe acute respiratory syndrome coronavirus 2 that neutralizes antibodies, reduced the risk of COVID-19-related hospitalization or death in studies conducted before the emergence of the Omicron variant. The objective of this study is to evaluate the clinical efficacy of sotrovimab in patients with mild to moderate COVID-19 Omicron BA.1 and BA.2 subvariant infections using a propensity score matching method. The propensity score-matched cohort study population was derived from patients who received sotrovimab. We derived a comparator group from an age- and sex-matched population who were recuperating in a medical facility after COVID-19 infection or from elderly person entrance facilities during the same period who were eligible for but did not receive sotrovimab treatment. In total, 642 patients in the BA.1 subvariant group and 202 in the BA.2 subvariant group and matched individuals were analyzed. The outcome was the requirement for oxygen therapy. In the treatment group, 26 patients with the BA.1 subvariant and 8 patients with the BA.2 subvariant received oxygen therapy. The administration of oxygen therapy was significantly lower in the treatment group than in the control group (BA.1 subvariant group, 4.0% vs. 8.7%, p = 0.0008; BA.2 subvariant group, 4.0% vs. 9.9%, p = 0.0296). All these patients were admitted to our hospitals and received additional therapy and then recovered. No deaths were observed in either group. Our results demonstrate that the sotrovimab antibody treatment may be associated with a reduction in the requirement for oxygen therapy among high-risk patients with mild to moderate COVID-19 Omicron BA.1 and BA.2 subvariants.
引用
收藏
页数:8
相关论文
共 20 条
[1]  
Addetia A, 2023, bioRxiv, DOI [10.1101/2023.01.17.523798, 10.1101/2023.01.17.523798v2, DOI 10.1101/2023.01.17.523798, 10.1101/2023.01.17.523798]
[2]   Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients [J].
Aggarwal, Neil R. ;
Beaty, Laurel E. ;
Bennett, Tellen D. ;
Carlson, Nichole E. ;
Davis, Christopher B. ;
Kwan, Bethany M. ;
Mayer, David A. ;
Ong, Toan C. ;
Russell, Seth ;
Steele, Jeffrey ;
Wogu, Adane F. ;
Wynia, Matthew K. ;
Zane, Richard D. ;
Ginde, Adit A. .
JOURNAL OF INFECTIOUS DISEASES, 2022, 226 (12) :2129-2136
[3]   Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies [J].
Bruel, Timothee ;
Stefic, Karl ;
Nguyen, Yann ;
Toniutti, Donatella ;
Staropoli, Isabelle ;
Porrot, Francoise ;
Guivel-Benhassine, Florence ;
Bolland, William-Henry ;
Planas, Delphine ;
Hadjadj, Jerome ;
Handala, Lynda ;
Planchais, Cyril ;
Prot, Matthieu ;
Simon-Loriere, Etienne ;
Andre, Emmanuel ;
Baele, Guy ;
Cuypers, Lize ;
Mouthon, Luc ;
Mouquet, Hugo ;
Buchrieser, Julian ;
Seve, Aymeric ;
Prazuck, Thierry ;
Maes, Piet ;
Terrier, Benjamin ;
Hocqueloux, Laurent ;
Schwartz, Olivier .
CELL REPORTS MEDICINE, 2022, 3 (12)
[4]   Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains [J].
Case, James Brett ;
Mackin, Samantha ;
Errico, John M. ;
Chong, Zhenlu ;
Madden, Emily A. ;
Whitener, Bradley ;
Guarino, Barbara ;
Schmid, Michael A. ;
Rosenthal, Kim ;
Ren, Kuishu ;
Dang, Ha, V ;
Snell, Gyorgy ;
Jung, Ana ;
Droit, Lindsay ;
Handley, Scott A. ;
Halfmann, Peter J. ;
Kawaoka, Yoshihiro ;
Crowe, James E., Jr. ;
Fremont, Daved H. ;
Virgin, Herbert W. ;
Loo, Yueh-Ming ;
Esser, Mark T. ;
Purcell, Lisa A. ;
Corti, Davide ;
Diamond, Michael S. .
NATURE COMMUNICATIONS, 2022, 13 (01)
[5]  
Dillen J, 2021, bioRxiv, DOI [10.1101/2021.03.09.434607, 10.1101/2021.03.09.434607, 10.1101/2021.03.09.434607v4]
[6]   Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA [J].
Cheng, Mindy M. M. ;
Reyes, Carolina ;
Satram, Sacha ;
Birch, Helen ;
Gibbons, Daniel C. C. ;
Drysdale, Myriam ;
Bell, Christopher F. F. ;
Suyundikov, Anvar ;
Ding, Xiao ;
Maher, M. Cyrus ;
Yeh, Wendy ;
Telenti, Amalio ;
Corey, Lawrence .
INFECTIOUS DISEASES AND THERAPY, 2023, 12 (02) :607-621
[7]   Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial [J].
Gupta, Anil ;
Gonzalez-Rojas, Yaneicy ;
Juarez, Erick ;
Casal, Manuel Crespo ;
Moya, Jaynier ;
Falci, Diego Rodrigues ;
Sarkis, Elias ;
Solis, Joel ;
Zheng, Hanzhe ;
Scott, Nicola ;
Cathcart, Andrea L. ;
Parra, Sergio ;
Sager, Jennifer E. ;
Austin, Daren ;
Peppercorn, Amanda ;
Alexander, Elizabeth ;
Yeh, Wendy W. ;
Brinson, Cynthia ;
Aldinger, Melissa ;
Shapiro, Adrienne E. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (13) :1236-1246
[8]   Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab [J].
Gupta, Anil ;
Gonzalez-Rojas, Yaneicy ;
Juarez, Erick ;
Casal, Manuel Crespo ;
Moya, Jaynier ;
Falci, Diego R. ;
Sarkis, Elias ;
Solis, Joel ;
Zheng, Hanzhe ;
Scott, Nicola ;
Cathcart, Andrea L. ;
Hebner, Christy M. ;
Sager, Jennifer ;
Mogalian, Erik ;
Tipple, Craig ;
Peppercorn, Amanda ;
Alexander, Elizabeth ;
Pang, Phillip S. ;
Free, Almena ;
Brinson, Cynthia ;
Aldinger, Melissa ;
Shapiro, Adrienne E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (21) :1941-1950
[9]   Effectiveness of Casirivimab-lmdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge A Cohort Study and Randomized Comparative Effectiveness Trial [J].
Huang, David T. ;
McCreary, Erin K. ;
Bariola, J. Ryan ;
Minnier, Tami E. ;
Wadas, Richard J. ;
Shovel, Judith A. ;
Albin, Debbie ;
Marroquin, Oscar C. ;
Kip, Kevin E. ;
Collins, Kevin ;
Schmidhofer, Mark ;
Wisniewski, Mary Kay ;
Nace, David A. ;
Sullivan, Colleen ;
Axe, Meredith ;
Meyers, Russell ;
Weissman, Alexandra ;
Garrard, William ;
Peck-Palmer, Octavia M. ;
Wells, Alan ;
Bart, Robert D. ;
Yang, Anne ;
Berry, Lindsay R. ;
Berry, Scott ;
Crawford, Amy M. ;
McGlothlin, Anna ;
Khadem, Tina ;
Linstrum, Kelsey ;
Montgomery, Stephanie K. ;
Ricketts, Daniel ;
Kennedy, Jason N. ;
Pidro, Caroline J. ;
Nakayama, Anna ;
Zapf, Rachel L. ;
Kip, Paula L. ;
Haidar, Ghady ;
Snyder, Graham M. ;
McVerry, Bryan J. ;
Yealy, Donald M. ;
Angus, Derek C. ;
Seymour, Christopher W. .
JAMA NETWORK OPEN, 2022, 5 (07) :E2220957
[10]  
Iketani S, 2022, NATURE, V604, P553, DOI 10.1038/s41586-022-04594-4